Skip to content

Source filing unavailable

Q2 2018 · —
Revenue$5.70M−62.9% vs Q2 2017−1.5% vs Q1 2018
Net Income-$11.54MN/M vs Q2 2017N/M vs Q1 2018
EPS Diluted-$24.17N/M vs Q2 2017N/M vs Q1 2018
Operating Income-$12,088,000—
Operating Cash Flowderived-$13,945,000—
Free Cash Flowderived-$13,981,000—
Margins · derived
Operating margin-211.9%
Net margin-202.3%−190.5 pt vs Q2 2017

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2018Q2 2017
Revenue$5.70M$15.36M
Net Income-$11.54M-$1.81M
EPS Diluted-$24.17-$4.07

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR